10 recruiting, 3 active not recruiting, 3 completed, 3 not yet recruiting. 20 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Recruiting 10, Active not recruiting 3, Completed 3, Not yet recruiting 3, Terminated 1 |
| Phase 1 | 6 | Recruiting 3, Completed 2, Terminated 1 |
Follow Mantle Cell Lymphoma (MCL): new trials by email Literature Review of Mantle Cell Lymphoma (MCL) trials Research Report on Mantle Cell Lymphoma (MCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma TT-01488 Tablets, Rituximab, Immunomodulatory Agent - Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | TransThera Sciences (Nanjing), Inc. | 188 | 2026-10-10 | 2026-10-02 |
| Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine - Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | Miltenyi Biomedicine GmbH | 52 | 2026-09-01 | 2026-05-06 |
| A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma 7×19-THEMIS CAR-T cells - Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 70 | 2026-09-01 | 2026-08-26 |
| Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) Orelabrutinib, Obinutuzumab, Venetoclax - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 39 | 2026-07-15 | 2026-07-22 |
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
| Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy Lisaftoclax, Pirtobrutinib - Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 45 | 2026-06-30 | 2026-07-06 |
| Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma Pirtobrutinib and rituximab - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 50 | 2025-09-30 | 2025-12-16 |
| Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma Autoleucel (Relmacabtagene Autoleucel), Sintilimab (PD-1 inhibitor) - Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Sun Yat-sen University | 30 | 2025-09-15 | 2026-01-21 |
| Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease Orelabrutinib, Rituximab (R), Lisaftoclax (APG-2575) - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Ruijin Hospital | 25 | 2025-09-10 | 2026-07-28 |
| Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment Orelabrutinib, Rituximab (R), BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Ruijin Hospital | 45 | 2025-07-01 | 2025-09-30 |
| Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma Acalabrutinib, Rituximab - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Sun Yat-sen University | 50 | 2025-04-14 | 2025-06-03 |
| A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma Acalabrutinib, Venetoclax, Rituximab - Mantle Cell Lymphoma (MCL) | Phase 2 | Active not recruiting | AstraZeneca | 108 | 2023-12-13 | 2026-09-02 |
| A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma Rocbrutinib - Mantle Cell Lymphoma (MCL) | Phase 2 | Active not recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 62 | 2023-02-21 | 2026-01-15 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| DALY II USA/ MB-CART2019.1 for DLBCL zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Miltenyi Biomedicine GmbH | 315 | 2021-05-25 | 2026-07-13 |
| Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma Ibrutinib, Venetoclax - Mantle Cell Lymphoma (MCL) | Phase 2 | Completed | AbbVie | 13 | 2020-09-23 | 2026-08-28 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells - Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL) | Phase 1 / Phase 2 | Recruiting | Medical College of Wisconsin | 100 | 2020-05-18 | 2026-02-23 |
| A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma Copanlisib, Ibrutinib - Mantle Cell Lymphoma (MCL) | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 8 | 2019-03-13 | 2022-12-14 |
| An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma ACP-196 (acalabrutinib) - Mantle Cell Lymphoma (MCL) | Phase 2 | Active not recruiting | Acerta Pharma BV | 124 | 2015-03-02 | 2026-08-04 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
Lymphoma, Mantle-Cell (20) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, Follicular (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell (4) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, B-Cell, Marginal Zone (2) · Recurrence (2) · Waldenstrom Macroglobulinemia (2) · Burkitt Lymphoma (1) · Central Nervous System Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Hairy Cell (1) · Multiple Myeloma (1)
Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphatic Diseases (20) · Lymphoproliferative Disorders (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Lymphoma (17) · Lymphoma, Non-Hodgkin (17) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Chronic Disease (4) · Hematologic Diseases (4) · Leukemia (4)
Rituximab (6) · acalabrutinib (4) · orelabrutinib (3) · venetoclax (3) · Cyclophosphamide (2) · Lisaftoclax (2) · fludarabine (2) · ibrutinib (2) · pirtobrutinib (2) · Adjuvants, Immunologic (1) · Bendamustine Hydrochloride (1) · Carmustine (1) · Cytarabine (1) · Etoposide (1) · Immune Checkpoint Inhibitors (1)
Acerta Pharma BV (2) · Guangzhou Lupeng Pharmaceutical Company LTD. (2) · Miltenyi Biomedicine GmbH (2) · Ruijin Hospital (2) · Sun Yat-sen University (2) · AbbVie (1) · AstraZeneca (1) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (1) · Henan Cancer Hospital (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1) · MingSight Pharmaceuticals, Inc (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · The First Affiliated Hospital with Nanjing Medical University (1) · TransThera Sciences (Nanjing), Inc. (1)
China (11) · United States (6) · Spain (3) · Australia (2) · Canada (2) · Poland (2) · United Kingdom (2) · Belgium (1) · Brazil (1) · Czechia (1) · France (1) · Italy (1) · Japan (1) · Netherlands (1) · Portugal (1)
Connie Batlevi, MD, PhD (1) · Johanna Theruvath, MD (1) · Jun Zhu, MD, PhD (1) · Nirav Shah, MD (1) · Wenbin Qian,Professor (1) · Yi Xia (1)
PMID 29241979, PMID 35597752, PMID 40163793, PMID 42212152
2023 (2), 2014 (1), U24HL138660 (1)